New antifungals drugs, new approaches and vaccines

Drupal spam blocked by CleanTalk.
Title Antifungal name Trial phase Datesort ascending
Patient-reported outcomes from two randomised studies comparing once-weekly application of amorolfine 5% nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis Amorolfine 9 Sep 2017
CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program. Biafungin (CD101) 8 Sep 2017
Drugs in Clinical Development for Fungal Infections (includes MAT023, encochleated amphotericin B)) Encochleated AmB (MAT023) 24 Aug 2017
Phase 2b Results of Viamet’s Oral VT-1161 for the Treatment of Recurrent Vulvovaginal Candidiasis (Presented at IDSOG Annual Meeting) VT-1161 Phase 2 11 Aug 2017
Efficacy and tolerability of amorolfine 5% nail lacquer in combination with systemic antifungal agents for onychomycosis: A meta-analysis and systematic review Amorolfine Phase 2 9 May 2017
Evaluation of the antifungal activity of SCY-078 in combination with other antifungals against Aspergillus strains Ibrexafungerp (SCY-078, MK-3118) 27 Apr 2017
In-vitro activity of F901318 and comparators against clinical isolates of cryptic species of Aspergillus F901318 (olorofim) 27 Apr 2017
A prospective, phase 2, multicentre, open-label, randomized, comparative study to estimate the safety, tolerability, pharmacokinetics, and efficacy of oral SCY-078 vsstandard-of-care following initial intravenous echinocandin therapy in the treatment of.. Ibrexafungerp (SCY-078, MK-3118) Phase 2 27 Apr 2017
Pharmacodynamics of F901318 against Aspergillus fumigatus in a rabbit model of invasive pulmonary aspergillosis (IPA) F901318 (olorofim) 27 Apr 2017
Antifungal peptides: a potential new class of antifungals for treating vulvovaginal candidiasis caused by fluconazole-resistant Candida albicans. P11-6 24 Apr 2017